Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.63 |
| ▸ | KDR | P35968 | 5/20 | 0.62 |
| ▸ | FLT1 | P17948 | 3/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.62 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.56 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.56 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.55 |
| ▸ | KIT | P10721 | 1/20 | 0.54 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | ABL2 | P42684 | 1/20 | 0.52 |
| ▸ | NSD2 | O96028 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3427416 | 0.94 | KDR (0.62) | EGFRKDRFLT1FGFR1EPHA2 | |
| SCHEMBL5754733 | 0.87 | ENPP1 (0.52) | EGFRKDRFLT1FGFR1EPHA2 | |
| SCHEMBL6017316 | 0.87 | ENPP1 (0.52) | EGFRKDRFLT1FGFR1EPHA2 | |
| SCHEMBL14489836 | 0.86 | EGFR (0.52) | EGFRKDRFLT1FGFR1EPHA2 | |
| SCHEMBL4087511 | 0.85 | EGFR (0.56) | EGFREPHB4ERBB2ENPP1 | |
| SCHEMBL14489848 | 0.85 | ACHE (0.57) | EGFREPHB4ERBB2ACHEBACE1 | |
| SCHEMBL14489831 | 0.85 | EGFR (0.66) | EGFRKDRFLT1FGFR1EPHA2 | |
| SCHEMBL3129523 | 0.85 | EGFR (0.56) | EGFREPHB4ERBB2ENPP1 | |
| SCHEMBL14489800 | 0.84 | EGFR (0.58) | EGFRKDRFLT1FGFR1EPHB4 | |
| SCHEMBL31193365 | 0.84 | ENPP1 (0.56) | EGFRKDRFLT1FGFR1EPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| US-20120046300-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | HENNEQUIN LAURENT FRANCOIS ANDRE (FR) | 2012-02-23 | — | — | US | disclosed |
| US-7989460-B2 | potent kinase insert domain-containing receptor (KDR) inhibitors with improved selectivity and pharmacokinetics; VEGF (vascular endothelial growth factor) inhibitors; cancer and rheumatoid arthritis; e.g. 7-(2-[4-(acetylmethyl)piperazin-1-yl]ethoxy)-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]quinazoline | ASTRAZENECA AB (SE) | 2011-08-02 | — | — | US | disclosed |
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080058342-A1 | Quinazoline Derivatives As Angiogenesis Inhibitors | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-7074800-B1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| EP-1553097-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | disclosed |
| EP-1154774-B1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058342-A1 | Quinazoline Derivatives As Angiogenesis Inhibitors | VEGFA, KDR, FLT1 | EGFR 273/4885KDR 2/4885FLT1 3/4885 |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | EGFR 500/4885KDR 3/4885FLT1 2/4885 |
| US-20120046300-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, KDR, FLT1 | EGFR 344/4885KDR 2/4885FLT1 3/4885 |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | FLT4, NOS3, FLT1 | EGFR 549/4885KDR 4/4885FLT1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.